POPULATION PHARMACOKINETICS OF PANTOPRAZOLE IN PATIENTS ON DUAL ANTIPLATELET THERAPY FOLLOWING ACUTE CORONARY SYNDROME
Authors:
- Valentina N. NikolićVNValentina N. Nikolić
- Dragana StokanovićDSDragana Stokanović
- Slobodan M. JankovićSJSlobodan M. Janković
- Sandra S. KonstatinovićSKSandra S. Konstatinović
- Jelena B. ZvezdanovićJZJelena B. Zvezdanović
- Jelena LilićJLJelena Lilić
- Nikola StefanovićNSNikola Stefanović
- Svetlana ApostolovićSASvetlana Apostolović
- Jasmina R. MilovanovićJMJasmina R. Milovanović
Open Access
- 13 April 2024
- journal article
- Published by University of Nis in Facta Universitatis, Series: Medicine and Biology
Abstract
This study investigates factors influencing pantoprazole pharmacokinetics (PK) in patients with acute coronary syndrome (ACS) undergoing dual antiplatelet therapy (DAPT) comprising acetylsalicylic acid and clopidogrel, alongside concomitant pantoprazole to mitigate gastrointestinal risks. We conducted a prospective analysis on 93 ACS patients, assessing pantoprazole PK parameters and their correlation with C-reactive protein (CRP) levels, indicative of inflammation. Blood samples for pantoprazole concentration and CRP levels were collected according to a predefined schedule, post-oral pantoprazole administration at steady state. The study highlights a notable influence of CRP levels on pantoprazole clearance, underscoring inflammation’s impact on drug metabolism. Elevated CRP was associated with altered pantoprazole pharmacokinetics, suggesting that inflammatory status significantly contributes to metabolic variability in this patient population. Our findings suggest the need for personalized pantoprazole dosing in ACS patients on DAPT, considering the inflammatory status as reflected by CRP levels. This approach could optimize therapeutic efficacy and minimize adverse effects, advancing personalized treatment strategies in the management of ACS.Keywords
All Related Versions
This publication has 19 references indexed in Scilit:
- Modeling Approach to Predict the Impact of Inflammation on the Pharmacokinetics of CYP2C19 and CYP3A4 SubstratesPharmaceutical Research, 2021
- An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genesJournal of Neural Transmission, 2018
- Chronic use of proton pump inhibitors, adverse events and potential biological mechanisms: A translational analysisTherapies, 2018
- Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicineExpert Opinion on Drug Metabolism & Toxicology, 2018
- A Systematic Comparison of the Impact of Inflammatory Signaling on Absorption, Distribution, Metabolism, and Excretion Gene Expression and Activity in Primary Human Hepatocytes and HepaRG CellsDrug Metabolism and Disposition, 2015
- CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteersEuropean Journal of Clinical Pharmacology, 2012
- Effects of Interleukin-6 (IL-6) and an Anti-IL-6 Monoclonal Antibody on Drug-Metabolizing Enzymes in Human Hepatocyte CultureDrug Metabolism and Disposition, 2011
- A comparison of the acid‐inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphismAlimentary Pharmacology & Therapeutics, 2009
- Expression of CYP3A4 mRNA Is Correlated With CYP3A4 Protein Level and Metabolic Activity in Human LiverJournal of Pharmacological Sciences, 2004
- Acute-Phase Proteins and Other Systemic Responses to InflammationNew England Journal of Medicine, 1999